
Swissmedic Approves IFINWIL® (Eflornithine) For Children Diagnosed With High-Risk Neuroblastoma (HRNB)
(MENAFN- PR Newswire) IFINWIL®: now approved in Switzerland1 Nine out of 10 cases of neuroblastoma occur in children under the age of five2 The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, July 8, 2025 /PRNewswire/ -- …